Evidence map›Paper›PMID 40152072›Full record

ArticleThe Journal of pathology2025

MicroRNA-371-373 cluster and methylome analysis suggests that a subset of 'somatic-type' malignancies arising in germ cell tumors may originate in yolk sac tumor components.

João Lobo, Nuno Tiago Tavares, Diana Fonseca, Carmen Jerónimo, Rui Henrique, Nicolas Wyvekens, Yiying Yang, Matija Snuderl, Fiona Maclean, Jennifer Gordetsky and 8 more

Abstract read
In one paragraph

Article in The Journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

João LoboDepartment of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC), Porto, Portugal.ORCID 0000-0001-6829-1391
Nuno Tiago TavaresCancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC) & CI-IPOP@RISE (Health Research Network), Porto, Portugal.ORCID 0000-0001-8426-1838
Diana FonsecaDepartment of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC), Porto, Portugal.
Carmen JerónimoCancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC) & CI-IPOP@RISE (Health Research Network), Porto, Portugal.ORCID 0000-0003-4186-5345
Rui HenriqueDepartment of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC), Porto, Portugal.ORCID 0000-0003-3171-4666
Nicolas WyvekensDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Yiying YangDepartment of Pathology, New York University, Langone Health, New York, NY, USA.
Matija SnuderlDepartment of Pathology, New York University, Langone Health, New York, NY, USA.ORCID 0000-0003-0752-0917
Fiona MacleanDepartment of Anatomical Pathology, Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.
Jennifer GordetskyDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Christopher Dm FletcherDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Michelle S HirschDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Muhammad T IdreesDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
Katrina CollinsDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
Laura WarmkeDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
Thomas M UlbrightDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
Andres M AcostaDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0001-8817-6331

Funding

Fundação para a Ciência e a Tecnologia 2022.09566.BDmiREpiTestis PI190-CI-IPOP-23-2023
6 · The paper itself

Abstract

Somatic-type malignancies (SMs) arising in germ cell tumors (GCTs) are aggressive neoplasms resistant to systemic treatment. Most are diagnosed in metastatic sites after chemotherapy; however, they have also been well-documented in primary testicular GCTs. Historically, SMs were thought to originate in components of teratoma that acquire molecular alterations equivalent to those that characterize their true somatic counterparts. However, recent studies have shown that SMs typically lack the hallmark molecular alterations seen in similar somatic tumors. Additionally, clinicopathologic and molecular data suggest that a subset may derive from yolk sac tumor (YST) rather than teratoma. In this study, we evaluated the relationship between conventional histological types of GCTs and SMs by comparing expression of microRNA (miR)-371-373 and genomic methylation profiles. A total of 96 samples (including multiple paired conventional GCT-SM samples from individual tumors) were assessed for miR-371-373 expression by RT-qPCR and genomic DNA methylation using a clinically validated assay. Expression of miR-371-373 was higher in conventional GCTs than in SMs (considered as a single category encompassing all histological subtypes). However, miR-371-373 expression was heterogeneous among SMs, with significantly higher levels in sarcomatoid YST (SYST) and glandular neoplasms than in other SMs. Genomic DNA methylation analysis showed that SMs (considered as a single category) did not form a distinct cluster. Instead, they grouped into multiple clusters that did not show perfect correspondence with histology and often included conventional GCTs. Genome-wide methylation assessment showed a higher abundance of hypermethylated regions in SMs than in conventional GCTs. Analysis of paired conventional GCT and 'somatic-type' components that did not meet size criteria for SMs dissected from individual tumors demonstrated separation according to histology, suggesting that epigenetic processes play a role in the transition from conventional GCT to 'somatic-type' phenotypes. Gene-level and pathway-level analyses identified MAPK/RAS signaling, mitosis/proliferation, differentiation towards neural tissue/neuroectoderm, epithelial-to-mesenchymal transition, and DNA repair as key differentially regulated processes in components with somatic-type histology, suggesting mechanisms of progression from conventional to 'somatic' phenotypes in GCT. These results support the hypothesis that a subset of SMs derive from YST and suggest that some subtypes (such as SYST) may represent 'intermediate' phenotypes. Additionally, analysis of differentially methylated promoter regions in SM identified genes and biologic processess that may underlie 'somatic tranformation' in GCTs. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

Biomarkers, TumorDNA MethylationEndodermal Sinus TumorMicroRNAsNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsAdultEpigenesis, GeneticEpigenomeGene Expression Regulation, NeoplasticHumansMaleBiomarkers, TumorMicroRNAsMIRN371 microRNA, humanMIRN373 microRNA, humanDNA methylationepigeneticsmicroRNA‐371–373somatic‐type malignancytesticular germ cell tumorsyolk sac tumor

Identifiers

PMID40152072
PMCPMC12056289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.